The effects of different intensities of aerobic exercise for 8 weeks on neurogenesis, depression, and anxiety in young mice.

Atopic dermatitis is a chronic inflammatory skin disease that affects not only the skin but also mental well-being, with many patients experiencing depressive symptoms and fatigue. This real-world study analysed data from 633 adults in the German TREATgermany registry treated with dupilumab, an antibody therapy. Within 3 months, depressive symptoms and fatigue showed substantial improvement, which persisted over 12 months. Patients with a high mental health burden at the start benefited just as much as those with less burden. The findings indicate that dupilumab is associated with improvements not only in skin symptoms but also the psychological well-being of patients with atopic dermatitis. Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterised by intense pruritus, xerosis and eczematous lesions. It affects approximately 20% of children and adolescents and 4–5% of adults in industrialized countries (, ). Beyond the cutaneous symptoms, patients with moderate-to-severe AD often experience a considerable disease burden due to a high prevalence of psychiatric comorbidities, including depression, anxiety disorders and attention deficit/hyperactivity disorder (ADHD) (–). These mental health impairments contribute to substantial reductions in health-related quality of life and can complicate disease management. Several mechanisms are implicated in the increased psychiatric morbidity among AD patients. These include chronic sleep disruption, emotional distress linked to visible skin lesions, experiences of social rejection or discrimination and substance abuse (–). Furthermore, AD-related chronic systemic inflammation and neuroimmune dysregulation may contribute to the pathophysiology of depression and fatigue (). This gives rise to a potential bidirectional relationship between psychological stress and AD severity.